The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
Abstract
The GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission (CR) achievement and length, the influence of the addition of cyclophosphamide (random I) to a conventional 4-drug induction on CR rate and duration, and whether an early post-CR intensification (random II) by an 8-drug consolidation could improve CR duration. Median follow-up of this study was 7.3 years. From January 1988 to April 1994, among 794 adult (> 12 but < 60 years) patients registered, 778 were eligible. Their median age was 27.5 years; 73% had B-lineage acute lymphoblastic leukemia (ALL) and 22% had T-lineage disease; 18% showed associated myeloid markers; 47 of 216 analyzed patients (22%) had Philadelphia chromosome–positive ALL. Response to PDN pretreatment was observed in 65% of cases. CR was achieved in 627 patients (82%). Resistant patients and induction death rates were 11% and 7%, respectively. Random II was applied to 388 patients with CR; 201 had maintenance alone and 187 had consolidation followed by maintenance. The relapse rate was 60%; isolated central nervous system relapses were 8% of all CRs and 13% of all relapses. Median survival (overall survival [OS]), continuous complete remission (CCR), and disease-free survival (DFS) were 2.2, 2.4, and 2 years, respectively. PDN pretreatment response resulted the main independent factor influencing CR achievement, OS, CCR, and DFS; the addition of cyclophosphamide in induction significantly influenced CR achievement in a multivariate analysis. Neither induction intensification nor early consolidation appeared to influence CCR and DFS duration. For the first time PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Larson, R., Dodge, R., Burns, C., Lee, E., Stone, R., Schulman, P., Duggan, D., Davey, F., Sobol, R., & Frankel, Sr. (1995) · Blood · doi:10.1182/blood.v85.8.2025.bloodjournal8582025 · Cited by 626
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Aricò, M., Valsecchi, M. G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004063421402 · Cited by 600
Dördelmann, M., Reiter, A., Borkhardt, A., Ludwig, W.-D., Götz, N., Viehmann, S., Gadner, H., Riehm, H., & Schrappe, M. (1999) · Blood · doi:10.1182/blood.v94.4.1209 · Cited by 341
Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., & Furukawa, Y. (2001) · Blood · doi:10.1182/blood.v97.7.1999 · Cited by 262
Pui, C.-H., Mahmoud, H. H., Rivera, G. K., Hancock, M. L., Sandlund, J. T., Behm, F. G., Head, D. R., Relling, M. V., Ribeiro, R. C., Rubnitz, J. E., et al. (1998) · Blood · doi:10.1182/blood.v92.2.411 · Cited by 209
Gaynor, J., Chapman, D., Little, C., McKenzie, S., Miller, W., Andreeff, M., Arlin, Z., Berman, E., Kempin, S., & Gee, T. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.1014 · Cited by 170
Toyoda, Y., Manabe, A., Tsuchida, M., Hanada, R., Ikuta, K., Okimoto, Y., Ohara, A., Ohkawa, Y., Mori, T., Ishimoto, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1508 · Cited by 107
Kamps, W. A., Bökkerink, J. P. M., Hählen, K., Hermans, J., Riehm, H., Gadner, H., Schrappe, M., Slater, R. M., Ruiter, E. V. D. B.-D., Smets, L. A., et al. (1999) · PubMed · Cited by 107
Nonparametric confidence limits for survival probabilities and median survival time.
Simon, R. M., & Yj, L. (1982) · PubMed · Cited by 98
New approaches to acute lymphoblastic leukemia in adults: where do we go?
Hoelzer, D. T., & Gökbuget, N. (2000) · PubMed · Cited by 97
Cited by
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Goldstone, A. H., Richards, S. M., Lazarus, H. M., Tallman, M. S., Buck, G., Fielding, A. K., Burnett, A. K., Chopra, R., Wiernik, P. H., Foroni, L., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116582 · Cited by 778
Metadata
- Authors
- Annino, L., Vegna, M. L., Camera, A., Specchia, G., Visani, G., Fioritoni, G., Ferrara, F., Peta, A., Ciolli, S., Deplano, W., Fabbiano, F., Sica, S., Di Raimondo, F., Cascavilla, N., Tabilio, A., Leoni, P., Invernizzi, R., Baccarani, M., Rotoli, B., Amadori, S., & Mandelli, F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-02-01
- Volume
- 99
- Issue
- 3
- Pages
- 863-871
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2107685938
- Cited by
- 352
- References
- 18
- FWCI
- 17.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.